Dr. Ashok Pralhad Waghmare


BACKGROUND: Multidrug-resistant tuberculosis (MDR-TB) and extensively drug-resistant tuberculosis (XDR- TB) are the major public
health problem that threatens the progress in disease care and control worldwide. The treatment of MDR-TB with second line drug is prolonged,
complex, and expensive, having high rate of mortality along with the considerable rate of adverse effects. But the treatment efficacy rates in MDRTB
are the key issue that cannot be ignored and this present study aims to evaluate the treatment outcomes and potential factors associated in
patients with MDR-TB infections.
METHOD: - A retrospective cohort study was carried out among the enrolled in DOTS-Plus program with MDR-TB are 287 no. of patients from
2012 to 2018 in Tuberculosis department, Ashwini Rural Medical College Hospital and Research Centre Kumbhari, Solapur, Karnataka, India. The
patients necessary information such as demographics, clinical parameters, if any previous TB treatment history and treatment outcomes to Cat IV
anti-TB therapy, any interruptions in treatment, adverse drug reactions, culture conversion etc. were evaluated from the records.
RESULTS: Out of 287 patients, 32 (11.15%) had a successful cured after complete course of ATT). Remaining 153 patients had an unsuccessful
outcome (death (27.53%), default (20.56%), failure or switched to Cat V (5.23%), and 75 patients (25.09%) are on treatment.
CONCLUSION:-The treatment success rate revealed that MDR TB patients has shown low treatment success rate. Patients still on treatment and
High default treatment percentage had been observed, which could be the possible reason.


Multidrug-resistant Tuberculosis (MDR-TB), Extensively Drug-resistant Tuberculosis (XDR- TB), Second-line Drugs, Treatment Outcome.

Full Text:



World Health Organization. Global Tuberculosis Report; 2016.

Arora V, Sarin R, Singla R, Khalid UK, Mathuria K, Singla, N, et al. DOTS-Plus for patients with multidrug-resistant tuberculosis in India: early results after three years. Indian J Chest Dis Allied Sci. 2007;49:75-9.

Jain K, Desai M, Solanki R, Dikshit RK. Treatment outcome of standardized regimen in patients with multidrug resistant tuberculosis. J PharmacolPharmacother. 2014;5:145-9.

Patel S, Nimavat KB, Alpesh PB, Shukla LK, Shringarpure KS, Mehta KG, et al. Treatment outcome among cases of multidrug-resistant tuberculosis (MDRTB) in Western India: A prospective study. J Infect Public Health. 2016;9:478-84.

Central TB division. Guidelines on programmatic management of drug resistant TB (PMDT) in India. India: Directorate General of Health Services MoHFW; 2012.

Getachew T, Bayray A, Weldearegay B. Survival and predictors of mor-tality among patients under multi-drug resistant tuberculosis treatment in Ethiopia: St. Peter’s specialized Tuberculosis hospital, Ethiopia. Int J Pharm Sci Res. 2013; 4: 776-787.

Balabanova Y, Radiulyte B, Davidaviciene E. Survival of drug resistant tuberculosis patients in Lithuania: retrospective national cohort study. BMJ Open 2011;1: e000351.

Farley JE, Ram M, Pan W. Outcomes of Multi-Drug Resistant Tubercu-losis (MDR-TB) among a Cohort of South African Patients with High HIV Prevalence. PLoS ONE 2011; 6: e20436.

USAID/Ethiopia. HELP Ethiopia address the low TB performance (HE-AL-TB) midterm evaluation. USAID 2014.

World health organization. Tuberculosis MDR-TB & XDR-TB prog-ress report; 2011.

World Health Organization (WHO). Multidrug-resistant tuberculosis (MDR-TB) 2015 update. Geneva: WHO; 2015.

Dennis F, Fuad M, Fraser W, Inés B, Matteo Z, Nguyen L, et al. Mul-tidrug-resistant tuberculosis around the world: what progress has been made? EurRespir J 2015; 45:150–160.

Kibret KT, Moges Y, Memiah P, Biadgilign S. Treatment outcomes for multidrug-resistant tuberculosis under DOTS-Plus: a systematic review and meta-analysis of published studies. Infect Dis Poverty. 2017;6:7.

Johnston JC, Shahidi NC, Sadatsafavi M, Fitzgerald JM. Treatment outcomes of multidrug-resistant tuberculosis: a systematic review and meta-analysis. PloS one. 2009;4:e6914.

Orenstein EW, Basu S, Shah NS, Andrews JR, Friedland GH, Moll AP, et al. Treatment outcomes among patients with multidrug-resistant tuberculosis: systematic review and meta-analysis. Lancet Infect Dis. 2009;9:153-61.


  • There are currently no refbacks.